实用癌症杂志
實用癌癥雜誌
실용암증잡지
The Practical Journal of Cancer
2015年
12期
1846-1848,1851
,共4页
肺癌%晚期%吉西他滨%顺铂%经支气管动脉药物灌注%疗效
肺癌%晚期%吉西他濱%順鉑%經支氣管動脈藥物灌註%療效
폐암%만기%길서타빈%순박%경지기관동맥약물관주%료효
Lung cancer%Advanced%Gemcitabine%Cisplatin%Bronchial artery infusion%Efficacy
目的：探讨吉西他滨联合顺铂动、静脉联合化疗治疗晚期非小细胞肺癌（ NSCLC）的疗效与安全性。方法按照随机数字表的分组方法将136例患者分为对照组和观察组，各68例。对照组给予注射用盐酸吉西他滨1000 mg／m2、顺铂注射液50 mg／m2静脉滴注化疗治疗。观察组于第1天经支气管动脉药物灌注吉西他滨1000 mg／m2＋顺铂50 mg／m2，于第8天再次给予吉西他滨1000 mg／m2静脉滴注化疗治疗。分析2组近期治疗总有效率、生活质量改善情况及不良反应。结果观察组近期治疗总有效率高于对照组，2组差异有统计学意义（P＜0．05）。观察组中鳞癌及中央型肺癌患者的临床治疗有效率分别高于腺癌及周围型肺癌患者，2组差异均有统计学意义（P均＜0．05）。观察组生活质量改善率高于对照组，且与对照组比较，差异有统计学意义（ P＜0．05）。2组不良反应发生率经统计学比较，差异无统计学意义（ P＞0．05）。结论吉西他滨、顺铂动、静脉联合化疗治疗晚期NSCLC患者，可提高患者的临床治疗有效率，改善患者的生活质量，具有较高的安全性。
目的：探討吉西他濱聯閤順鉑動、靜脈聯閤化療治療晚期非小細胞肺癌（ NSCLC）的療效與安全性。方法按照隨機數字錶的分組方法將136例患者分為對照組和觀察組，各68例。對照組給予註射用鹽痠吉西他濱1000 mg／m2、順鉑註射液50 mg／m2靜脈滴註化療治療。觀察組于第1天經支氣管動脈藥物灌註吉西他濱1000 mg／m2＋順鉑50 mg／m2，于第8天再次給予吉西他濱1000 mg／m2靜脈滴註化療治療。分析2組近期治療總有效率、生活質量改善情況及不良反應。結果觀察組近期治療總有效率高于對照組，2組差異有統計學意義（P＜0．05）。觀察組中鱗癌及中央型肺癌患者的臨床治療有效率分彆高于腺癌及週圍型肺癌患者，2組差異均有統計學意義（P均＜0．05）。觀察組生活質量改善率高于對照組，且與對照組比較，差異有統計學意義（ P＜0．05）。2組不良反應髮生率經統計學比較，差異無統計學意義（ P＞0．05）。結論吉西他濱、順鉑動、靜脈聯閤化療治療晚期NSCLC患者，可提高患者的臨床治療有效率，改善患者的生活質量，具有較高的安全性。
목적：탐토길서타빈연합순박동、정맥연합화료치료만기비소세포폐암（ NSCLC）적료효여안전성。방법안조수궤수자표적분조방법장136례환자분위대조조화관찰조，각68례。대조조급여주사용염산길서타빈1000 mg／m2、순박주사액50 mg／m2정맥적주화료치료。관찰조우제1천경지기관동맥약물관주길서타빈1000 mg／m2＋순박50 mg／m2，우제8천재차급여길서타빈1000 mg／m2정맥적주화료치료。분석2조근기치료총유효솔、생활질량개선정황급불량반응。결과관찰조근기치료총유효솔고우대조조，2조차이유통계학의의（P＜0．05）。관찰조중린암급중앙형폐암환자적림상치료유효솔분별고우선암급주위형폐암환자，2조차이균유통계학의의（P균＜0．05）。관찰조생활질량개선솔고우대조조，차여대조조비교，차이유통계학의의（ P＜0．05）。2조불량반응발생솔경통계학비교，차이무통계학의의（ P＞0．05）。결론길서타빈、순박동、정맥연합화료치료만기NSCLC환자，가제고환자적림상치료유효솔，개선환자적생활질량，구유교고적안전성。
Objective To investigate the efficacy and safety of gemcitabine combined with cisplatin arterial and intrave-nous chemotherapy for advanced non-small cell lung cancer (NSCLC).Methods 133 patients were randomly divided into the control group and the observation group,68 cases in each.The control group were treated with gemcitabine(1 000 mg/m2 ) and cisplatin(50 mg/m2).And the observation group were treated with gemcitabine(1 000 mg/m2) and cisplatin(50 mg/m2) through bronchial artery infusion at the first day,and then were given gemcitabine(1 000 mg/m2 ) at the 8th day through intrave-nous.The total effective rate of recent treatment,improvement rate of quality life and adverse reactions of the 2 groups were com-pared.Results The total effective rate in the observation group was significantly higher than that of the control group,the differ-ence was statistically significant (P<0.05).In the observation group,the total effective rate in patients with squamous cell carci-noma and central type lung cancer were higher than those of patients with adenocarcinoma and peripheral lung cancer( both P<0.05).The quality life improvement rate in the observation group was higher than that of the control group(P<0.05).The inci-dence of adverse reactions in the 2 groups had no statistically significant difference(P>0.05).Conclusion Gemcitabine com-bined with cisplatin arterial and intravenous chemotherapy for advanced NSCLC can improve the clinical efficiency,quality of life and has high security.
